Show simple item record

dc.contributor.authorKanwar, Nupur
dc.contributor.authorBakr, Mahmoud M
dc.contributor.authorMeer, Mohammed
dc.contributor.authorSiddiqi, Allauddin
dc.date.accessioned2020-09-29T01:13:34Z
dc.date.available2020-09-29T01:13:34Z
dc.date.issued2020
dc.identifier.issn0007-0610
dc.identifier.doi10.1038/s41415-020-1642-3
dc.identifier.urihttp://hdl.handle.net/10072/398002
dc.description.abstractIn the past, osteonecrosis of the jaw (ONJ) was generally reported with bisphosphonate drugs; hence, the term BRONJ (bisphosphonate-related osteonecrosis of the jaw) was initially proposed. This was followed by the term ARONJ (antiresorptive osteonecrosis of the jaw). More recently, other novel medications such as vascular endothelial growth factor (VEGF) inhibitors, tyrosine kinase inhibitors and humanised antibodies that affect osteoclastic action have been reported to initiate ONJ in several cases. For this reason, in 2014, the American Association of Oral and Maxillofacial Surgeons (AAOMS) changed the term to MRONJ - medication-related osteonecrosis of the jaw. The review primarily focuses on ONJ associated with emerging therapies for the management of bone disorders. This article sheds some light on the risk factors that predispose dental patients to the development of osteonecrosis, the mechanisms of drug therapies associated with MRONJ, and potential treatment and management regimes for MRONJ patients. The current review noted that the incidence and associated risk of MRONJ is significant with the new therapeutic agents discussed. Therefore, for optimised patient care, pharmacovigilance with the new medications is essential for dental professionals.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.ispartofpagefrom886
dc.relation.ispartofpageto892
dc.relation.ispartofissue11
dc.relation.ispartofjournalBritish Dental Journal
dc.relation.ispartofvolume228
dc.subject.fieldofresearchDentistry
dc.subject.fieldofresearchcode3203
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsDentistry, Oral Surgery & Medicine
dc.subject.keywordsMEDICATION-RELATED OSTEONECROSIS
dc.subject.keywordsBISPHOSPHONATE-RELATED OSTEONECROSIS
dc.titleEmerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationKanwar, N; Bakr, MM; Meer, M; Siddiqi, A, Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature, BRITISH DENTAL JOURNAL, 2020, 228 (11), pp. 886-892
dc.date.updated2020-09-29T01:12:25Z
gro.hasfulltextNo Full Text
gro.griffith.authorMeer, Mohammed
gro.griffith.authorBakr, Mahmoud


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record